Antiinfective applications of toll-like receptor 9 agonists.
about
Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesToll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNAThe Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in MiceActivation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaquesIn vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection modelImmunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvantsAdjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.B cell TLRs and induction of immunoglobulin class-switch DNA recombination.Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.Mechanisms of neutrophil accumulation in the lungs against bacteria.Deprived TLR9 expression in apparently healthy nasal mucosa might trigger polyp-growth in chronic rhinosinusitis patients.A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport.The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathyLiposome-nucleic acid immunotherapeutics.Synthetic oligonucleotides as modulators of inflammationA class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C.A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice.Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes.Toll-like receptors--sentries in the B-cell response.Immunoregulation of GVHD by triggering the innate immune system with CpG.Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections.Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species.Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.Engineering immunity in the mucosal niche against sexually transmitted infections.Toll-Like Receptors and Tissue Remodeling: The Pro/Cons Recent Findings.The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency.TLR9-based immunotherapy for the treatment of allergic diseases.Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation.Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing.TLR9 regulates adipose tissue inflammation and obesity-related metabolic disorders.
P2860
Q24624348-6A37C4E6-C1AB-456D-A56E-B4BCB7DCAAABQ24656078-BA3BC9FA-3C1D-463E-B6E2-57DC09C7813FQ28552440-56E0BC3C-A25F-42E8-BB8A-60F4D9B9D732Q31139969-F8914C82-DEED-4AEB-B064-4E61127DC44BQ33576071-5B0A8A89-B07B-4B14-9F72-21C8633660F6Q33698106-CFA80C52-748B-41CF-A98B-D412787DC817Q33760871-09B3A7B0-DBBE-40AF-A9A9-7A79A2360794Q33893517-01A5355A-2BF1-4FAA-A26E-8CCD264053D8Q33906558-7F953120-E4F6-4428-87E4-734B1DDF275AQ34026316-94D3EEBA-4F49-4AFC-B8A9-0E4DB48513EFQ34061934-29A0A793-4D45-4DA6-8A4F-AAD07FBF5540Q34359593-46AA2AB8-DF48-4278-9CAF-A19990F9AEF6Q34618963-1DFFF0CF-766A-4758-B5D2-CDDEA59D14ADQ36143091-328B4980-4FC6-4518-9E05-A65B5B2A9BACQ36179016-5270FE34-D5DC-4DDA-BF01-FEE107EF1083Q36517160-B85DACF1-DCA5-4BC1-90F4-7CBA37615A60Q36882257-D9FBD716-7C6F-4BA6-9426-92496502AB56Q37262108-6F4A4A75-6BC5-4B4B-BB4B-7B9C2AD76A9FQ37515643-E1FE7B87-8FAF-4BC9-AD09-D71ABD3588DEQ37643323-B7B40DD4-7A8C-4D22-93AC-C44FE91BEA2BQ37672658-96DDBF61-5311-44D6-A7E3-634DF2F8F404Q37810081-33D63D39-EFA6-42C4-9293-1D5074DD8238Q38011249-1E6A7617-45DB-4C3B-94B0-5D8E998C75AFQ38131836-B166483F-17BB-4217-8D03-ED7D56570342Q38217708-456CCF67-4EE1-46A5-B36F-6840E034EDAEQ38543768-4CED19D5-F192-4101-9EF1-06F344DF2188Q38561820-5114D660-537A-4727-AF74-2AD95C9AF1AAQ38665495-5AD808D1-ABA9-49E6-8DB4-6888D1AF3D52Q39000290-A1C1B29E-F202-4243-A557-E48E97F6CA55Q39001670-D6DFBABC-A0CE-400B-A093-D5DF928FE5F6Q39849800-DB14B1E4-EF86-440A-B8DE-3DACB5722231Q52925677-0A344FE2-4D2C-4389-9656-BB3329A8A6A7
P2860
Antiinfective applications of toll-like receptor 9 agonists.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antiinfective applications of toll-like receptor 9 agonists.
@en
type
label
Antiinfective applications of toll-like receptor 9 agonists.
@en
prefLabel
Antiinfective applications of toll-like receptor 9 agonists.
@en
P2860
P1476
Antiinfective applications of toll-like receptor 9 agonists.
@en
P2093
Arthur M Krieg
P2860
P304
P356
10.1513/PATS.200701-021AW
P577
2007-07-01T00:00:00Z